Tüdőrák: vizsgálatok itt: Kanada
141 of 157 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Edmonton, Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 890 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - 3. fázisTaking peoplePembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Where
- Kingston, Kitchener, Montreal, Trois-Rivières
- Életkor
- 18 év and over
- People
- 851 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00 - 3. fázisTaking peopleA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Where
- Halifax, Hamilton, Kingston, Montreal, Oshawa, Québec, Toronto
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00 - 3. fázisTaking peopleA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Where
- Montreal
- Életkor
- 18 év and over
- People
- 630 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00 - 2. fázisNot yet taking people in KanadaA Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC
- Where
- Brampton, Edmonton, Montreal, Toronto
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07941609 - 3. fázisTaking peopleJoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
- Where
- London, Mississauga, Montreal, Ottawa, Toronto
- Életkor
- 18 év and over
- People
- 272 worldwide
- Run by
- University of Texas Southwestern Medical Center
See details and how to joinNCT02468024 - 3. fázisTaking peopleLUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Where
- Edmonton, Montreal, Ottawa, Toronto
- Életkor
- 18 év and over
- People
- 734 worldwide
- Run by
- NovoCure GmbH
See details and how to joinNCT06216301 - 1. fázisTaking peopleA Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Where
- Toronto
- Életkor
- 18 év to 99 év
- People
- 600 worldwide
- Run by
- Erasca, Inc.
See details and how to joinNCT06983743 · EU 2026-525794-39-00 - 3. fázisTaking peopleMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
- Where
- Chicoutimi, Moncton, Montreal
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07431827 · EU 2024-517337-41-00 - 3. fázisTaking peopleA Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Where
- Hamilton, Kingston, Montreal, Ottawa
- Életkor
- 18 év and over
- People
- 876 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00 - 1/2. fázisNot yet taking people in KanadaA Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Where
- Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 171 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07939815 - 3. fázisTaking peopleA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- Halifax, Montreal, Québec, Regina, Saskatoon, Toronto
- Életkor
- 18 év to 100 év
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00 - 3. fázisTaking peopleA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Where
- Halifax, Hamilton, Montreal, Toronto, Trois-Rivières, Winnipeg
- Életkor
- 18 év and over
- People
- 348 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00 - 3. fázisTaking peopleTrial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Where
- Chicoutimi, Montreal, Rimouski
- Életkor
- 18 év and over
- People
- 363 worldwide
- Run by
- OSE Immunotherapeutics
See details and how to joinNCT06472245 - 3. fázisTaking peopleThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Where
- Abbotsford British Columbia, Montreal, Saint-Jérôme
- Életkor
- 18 év and over
- People
- 714 worldwide
- Run by
- Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00 - 2/3. fázisTaking peopleStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Where
- Calgary, Chicoutimi, Montreal, Toronto
- Életkor
- 18 év and over
- People
- 661 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07100080 - 3. fázisTaking peopleA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Where
- Edmonton, Toronto
- Életkor
- 18 év and over
- People
- 675 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07190248 · EU 2024-514500-14-00 - 3. fázisNot yet taking people in KanadaBL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
- Where
- Calgary, Greenfield Park
- Életkor
- 18 év and over
- People
- 550 worldwide
- Run by
- SystImmune Inc.
See details and how to joinNCT07625644 - 4. fázisTaking peopleDabrafenib and/or Trametinib Rollover Study
- Where
- Toronto
- Életkor
- 18 év to 100 év
- People
- 100 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00 - 3. fázisTaking peopleA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Where
- Greenfield Park, Montreal
- Életkor
- 18 év and over
- People
- 780 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312137 · EU 2023-508012-35-00 - 3. fázisFut, nem toborozA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Where
- Chicoutimi, Edmonton, Québec, Rimouski
- Életkor
- 18 év and over
- People
- 530 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06646276 · EU 2024-515740-23-00 - 3. fázisTaking peopleA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- Where
- Montreal, Ottawa, Toronto
- Életkor
- 18 év and over
- People
- 420 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07099898 - 3. fázisTaking peoplePhase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Where
- Brampton, Halifax, Hamilton, Moncton, Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07291037 · EU 2024-520101-39-00 - 3. fázisNot yet taking people in KanadaDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Where
- London, Sault Ste. Marie
- Életkor
- 18 év and over
- People
- 670 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07472517 · EU 2025-520565-51-00 - 3. fázisTaking peopleStudy of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
- Where
- Edmonton, Montreal, Regina, Vancouver
- Életkor
- 18 év and over
- People
- 850 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07680790 · EU 2026-526486-21-00